What it sells
Diagnostics.
Business model breakdown
Workflow: what inputs become what output?
Single blood draw, multi-modal cfDNA analysis (genomic, epigenomic, fragmentomic) to give first-trimester risk stratification for aneuploidy and preeclampsia (Aitios NIPPT).
Economics: what it saves and how it charges
Pre-commercial diagnostics startup; EUR 6.4M seed round; value claim is early risk identification so aspirin prevention can be targeted.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-09-15 | Seed | 6,4 Mio. Euro | — | news.google.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.